Stock

Cullinan Therapeutics, Inc. CGEM

$17.32+0.23%

All stocks Create account to unlock

Overview

CGEM market data

Price History

CGEM price chart

Valuation & Profitability

no valuation data

No Valuation Data Yet

Alpha Vantage and Twelve Data both returned no valuation metrics for CGEM. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.

Company news

6 captured

Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $37 Price Target · Jun 11, 2026, 1:44 PM

8-K filing — Cullinan Therapeutics, Inc. (CGEM) · Jun 10, 2026, 11:32 AM

Cullinan Therapeutics To Host An Immunology Day Event in New York City For Analysts And Institutional Investors On June 10 · May 26, 2026, 11:03 AM

The FDA Grants Orphan Drug Designation To Cullinan Therapeutics' CLN-049 For Relapsed/Refractory Acute Myeloid Leukemia · May 19, 2026, 11:15 AM

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress · May 18, 2026, 9:15 PM

Cullinan Therapeutics To Reveal Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress · May 18, 2026, 9:10 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock